Wechselwirkungen · Esbriet
Esbriet 267 mg film-coated tablets Esbriet 534 mg film-coated tablets Esbriet 801 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-124593 · Präparat HOS-095889
A Phase 1 interaction study evaluated the effect of cigarette smoking (CYP1A2 inducer) on the pharmacokinetics of pirfenidone. The exposure to pirfenidone in smokers was 50% of that observed in non-smokers. Smoking has the potential to induce hepatic enzyme production and thus increase medicinal product clearance and decrease exposure. Concomitant use of strong inducers of CYP1A2 including smoking should be avoided during Esbriet therapy based on the observed relationship between cigarette smoking and its potential to induce CYP1A2. Patients should be encouraged to discontinue use of strong inducers of CYP1A2 and to stop smoking before and during treatment with pirfenidone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-10T17:10:00Z · SHA-256 3e3a5c4d66ed5831a2ef489344c7c93da06904625148f6ce24c6f45c434d4ca2 · Passage 2429b94c578bd0a39ee35b6576ed52682d75e2a1495e69061fd3e396309e3733 · Zeichen 2521–3203 im Abschnitt